Influence of irbesartan on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
More details
Hide details
Department of Pharmaceutics, Bapatla College of Pharmacy, AndhraPradesh, India
Candasamy Mayuren   

PhD, Asst. Prof., Department of Pharmacology, Bapatla College of Pharmacy, Bapatla-522101, Guntur Dist, AndhraPradesh, India.
J Pre Clin Clin Res. 2008;2(2):127–132
The influence of irbesartan on the hypoglycemic effect of gliclazide was studied in normal/diabetic rats and normal rabbits. Gliclazide and irbesartan was studied at a dose of 1.44 mg/200 g, 5.4 mg/200 g in normal/diabetic rats and at a dose of 5.6 mg/1.5 kg, 21 mg/1.5 kg in rabbits, respectively. All the animals were fasted for 18 h prior to experimentation; during this period the animals were fed with water ad libitum. All the drugs used in this study were administered orally. The blood samples were collected at 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hours and analyzed for glucose levels by GOD/POD method in normal/diabetic rats and rabbits. The blood samples were also analysed for the gliclazide concentration by HPLC in rabbits. Gliclazide exhibited a maximum reduction of blood glucose levels at the 2nd and 8th hour in normal and diabetic rats and at the 3rd hour in rabbits. Irbesartan exhibited a maximum hypoglycemic activity at the 6th hour in normal rats. Although single dose interaction did not show much enhancement of the hypoglycemic activity of gliclazide, multiple dose study exhibited signifi cant potentiation of hypoglycemic activity of gliclazide eff ect on concurrent administration with irbesartan. The interaction was found to be predominantly pharmacodynamic as no significant interaction was observed pharmacokinetically. The study indicates that irbesartan pretreatment elevates the hypoglycemic effect of gliclazide by a possible rise in insulin sensitivity. The study also suggests the necessity to readjust the dose of gliclazide when used concomitantly with irbesartan.
Murthy TEGK, Mayuren C, Krishna MSR, Reddy TPK: Study of interaction between amlodipine besylate and gliclazide in healthy rats. Int J Pharm Biol Sci 2008, 2(1), 139-142.
Swami AM, Shetty SR, Kumar SMS, Rao NV: A study on drug-drug interaction of roxithromycin and anti-diabetic drugs. Indian Drugs 2005, 42(12), 808-813.
Bastaki S: Diabetes mellitus and its treatment. Int J Diab & Metabol 2005, 13, 111-134.
Satyanarayana S, Krishnaiah YSR, Eswar KK, Elisha IR, Kiran VVSK: Infl uence of quinidine, selegiline and amphotericin-B on the pharmacokinetics and pharmacodynamics of tolbutamide in rabbits. Indian Drugs 1998, 35(10), 640-644.
Rambhimaiah S, Suresh DK, Gupta VRM, Bheemachari, Prakash PR, Rao PS: Infl uence of metronidazole on the hypoglycemic aff ect of tobutamide in healthy albino rabbits. Indian Drugs 2003, 40(9), 535-538.
Groop LC: Sulfonylureas in NIDDM. Diabetes Care 1992, 15, 737- 754.
Lebovitz HE: Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994, 17, 1542-1544.
Melander A, Lebovitz HE, Faber OK: Sulfonylureas. Why, which and how? Diabetes Care 1990, 13(3), 18-25.
Goyal RK, Joshi SS, Shah TS: Eff ects of chronic treatment with Nitrendipine in streptozotocin-induced diabetic rats. Indian J Pharm Sci 1996, 58(3), 100-105.
Ramachandra SS, Bheemachari, Joshi VG, Kumar YA, Pandit J, Rao NV, Rambhimaiah S: Infl uence of Itraconazole on sulfonylureas-induced hypoglycemia in diabetic rats. Indian J Pharm Sci 2005, 67(6), 677- 680.
Satyanarayana S, Eswar KK: Infl uence of Nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Mol Cell Biochem 2006, 291, 101-105.
Lawrence DR, Bacharach AL: Evaluation of drug activities: Pharmacometrics. Academic Press, USA, 1964.
Trinder P: Determination of glucose in blood using glucose oxidase with an alternative glucose acceptor. Ann Clin Biochem 1969, 6, 24-27.
Dhanabal SP, Kokate CK, Ramanathan M, Elango K, Kumar EP, Subbaraj T, Manimaran S, Suresh B: Antihyperglycemic activity of Polygala arvensis in alloxan diabetic rats. Indian Drugs 2004, 41(11), 690-695.
Vetrichelvan T, Kavimani S, Gupta JK, Lakshmi NC: Eff ect of rifampicin on Trigonella Foenum Graecum (Fenugreek) induced hypoglycemia in rats. Indian J Pharm Sci 1998, 244-245.
Jia F, Guang L, Rang L, Changxioa L: Determination of gliclazide in human plasma by RP-HPLC. Asian J Drug Metab Pharmacokinet 2005, 5(2), 145-148.
Mohammad RR, Afshin M, Mohammad HT: A simple and sensitive HPLC method for determination of gliclazide in human serum. J Chromatogr B 2003, 785, 383-386.
El-Enany E: Spectrophotometric determination of gliclazide in pharmaceutical and biological fl uids through ternary complex formation with cosin and palladium (II). Farmaco 2004, 59(1), 63-69.
Seham AE, Siham ME, Salwa MN, Omar MEA, Mahmoud SA: Studies on the glycemic and lipidemic eff ect of monopril and losartan in normal and diabetic rats. Pharmacol Res 2004, 50, 131-136.
Taavitsainen P, Kiukaannieme K, Pelkonen O: In vitro inhibition screening of human hepatic P[450] enzymes by fi ve angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000, 56, 135-140.
Julie AS, Vitoon S, Cody JD, John SK, Erik JH: Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. Metabolism Clin Exp 2005, 54, 1659-1668.
Gopala Krishna Murthy TE, Mayuren C: Infl uence of calcium channel antagonist on the pharmacodynamics of a second-generation sulfonylurea in rats and rabbits. Asian J Pharm 2008, July-September, 163-166.
Satyanarayana S, Eswar Kumar K, Rajasekhar J, Thomas L, Rajanna S, Rajanna B: Infl uence of aqueous extract of fenugreek-seed powder on the pharmacodynamics and pharmacokinetics of gliclazide in rats/rabbits. Therapy 2007, 4(4), 457-463.
Michael S, Jurgen J, Ronald C, Thomas U, Ulrich K: Angiotensin type 1 receptor blocker induce peroxisome proliferator-activated receptor γ activity. Circulation 2004, 109, 2054-2057.
Eric JH, Stephen J, Tyson RK, Mary KT, Michael K: Selective angiotensin II receptor antagonism reduce insulin resistance in obese zucker rats. Hypertension 2001, 38, 884-890.